FilingSEC EDGAR8-K
Filana Therapeutics Receives Nasdaq Delisting Warning for Minimum Bid Price Deficiency
· SEC accepted
StageListing Deficiency
Filing content
The company received a notice from Nasdaq for failing to maintain the $1.00 minimum bid price requirement and has until March 16, 2027, to regain compliance.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…